# What Is IcoSema? Weekly Insulin and Semaglutide in One Shot | Buy This GLP

IcoSema combines weekly insulin icodec with semaglutide | three COMBINE trials, three comparators, and why the pooled HbA1c result carries 98% heterogeneity.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/what-is-icosema
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# What Is IcoSema? Weekly Insulin and Semaglutide in One Shot

The EU authorized this weekly insulin icodec and semaglutide combination as Kyinsu. Its glucose, weight and hypoglycemia results depended on the comparator.

Editorial profile: [Neil Sanders](https://buythisglp.com/authors/neil-sanders)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20267 min readUpdated November 2026

Estimated HbA1c difference, by comparator · COMBINE 1 · vs icodec alone · −0.66 · COMBINE 2 · vs semaglutide 1.0 mg · −0.44 · COMBINE 3 · vs basal-bolus insulin · −0.06 · Pool the first and third and the I² is 98%.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   IcoSema combines weekly insulin icodec and semaglutide. The EU authorized it as Kyinsu for type 2 diabetes.
-   Against icodec alone it lowered HbA1c 0.66 points more. Against basal-bolus insulin the gap was 0.06 points.
-   The two pooled HbA1c estimates differed substantially. I² was 98%.
-   Weight change favored IcoSema by 6.72 kg against basal-bolus insulin but rose 0.84 kg where semaglutide alone took off 3.70 kg.
-   The pooled analysis measured cardiovascular risk markers. It did not establish a reduction in heart attacks or strokes.

IcoSema is a once-weekly injection combining basal insulin icodec with semaglutide. It received EU marketing authorization as Kyinsu on November 24, 2025, for adults with type 2 diabetes inadequately controlled on basal insulin or GLP-1 receptor agonists, alongside diet, exercise and oral diabetes medicines [\[5\]](https://buythisglp.com/research/what-is-icosema#ref-5).

In October 2026, EMA’s medicines committee recommended extending that indication. The recommendation is a separate step from a change to the marketing authorization [\[6\]](https://buythisglp.com/research/what-is-icosema#ref-6). The [CagriSema diabetes trials](https://buythisglp.com/research/does-cagrisema-work-for-type-2-diabetes) studied a different combination. CagriSema contains cagrilintide and semaglutide, with no insulin in the combination itself.

## Three trials, three comparators

The first three COMBINE trials lasted 52 weeks and used different active comparators. The table reports estimated differences from those trials.

Week 52 results. COMBINE 2 shows weight changes in each group, and the other rows show weight differences.
| Trial | Compared with | HbA1c difference | Weight |
| --- | --- | --- | --- |
| COMBINE 1, n=1,291 | weekly insulin icodec | −0.66 points | −5.59 kg difference |
| COMBINE 2, n=683 | semaglutide 1.0 mg | −0.44 points | +0.84 kg vs −3.70 kg |
| COMBINE 3, n=679 | basal-bolus insulin | −0.06 points | −6.72 kg difference |

Week 52 results. COMBINE 2 shows weight changes in each group, and the other rows show weight differences.

In COMBINE 1, HbA1c fell 1.55 points on IcoSema and 0.89 points on weekly insulin icodec. The estimated difference was −0.66 points [\[2\]](https://buythisglp.com/research/what-is-icosema#ref-2). The meta-analysis reports a weight difference of −5.59 kg from this trial [\[1\]](https://buythisglp.com/research/what-is-icosema#ref-1).

COMBINE 2 enrolled adults already on a GLP-1. The estimated HbA1c difference was −0.44 points versus semaglutide 1.0 mg [\[3\]](https://buythisglp.com/research/what-is-icosema#ref-3). Weight went the other way: up 0.84 kg on IcoSema, down 3.70 kg on semaglutide.

COMBINE 3 compared weekly IcoSema with daily basal-bolus therapy. The HbA1c difference was −0.06 points (95% CI −0.22 to 0.09), meeting the trial’s noninferiority criterion [\[4\]](https://buythisglp.com/research/what-is-icosema#ref-4). Weight favored IcoSema by 6.72 kg.

## Why the pooled number reads 98%

A 2026 meta-analysis pooled COMBINE 1 and COMBINE 3, 1,970 people [\[1\]](https://buythisglp.com/research/what-is-icosema#ref-1). It left out COMBINE 2 for asking a different question.

The pooled HbA1c difference was −0.37 percentage points (95% CI −0.95 to 0.21). The I² was 98% [\[1\]](https://buythisglp.com/research/what-is-icosema#ref-1).

The studies differed in their estimated effects. Their different insulin comparators may help explain the inconsistency. With just two trials, the individual estimates are more informative for a specific comparison [\[1\]](https://buythisglp.com/research/what-is-icosema#ref-1).

## What moved beyond glucose

Compared with insulin-based regimens, pooled mean differences favored IcoSema for weight (−6.10 kg) and systolic blood pressure (−2.45 mmHg). LDL cholesterol and triglycerides each had an estimated treatment ratio of 0.94 [\[1\]](https://buythisglp.com/research/what-is-icosema#ref-1).

Hypoglycemia fell sharply against insulin. Severe or clinically significant episodes ran 0.14 per person-year of exposure versus 0.63 on icodec [\[2\]](https://buythisglp.com/research/what-is-icosema#ref-2). Against basal-bolus therapy they ran 0.21 versus 2.23 [\[4\]](https://buythisglp.com/research/what-is-icosema#ref-4). Compared with semaglutide alone, the trial detected no statistically significant difference [\[3\]](https://buythisglp.com/research/what-is-icosema#ref-3).

Our [guide to low blood sugar with insulin and GLP-1 medicines](https://buythisglp.com/research/can-a-glp1-cause-low-blood-sugar) explains why what a patient takes alongside a GLP-1 affects risk. IcoSema contains insulin.

Every one of those is a marker

Weight, blood pressure and lipids are risk markers. The pooled analysis did not test whether IcoSema reduces heart attacks, strokes or cardiovascular deaths [\[1\]](https://buythisglp.com/research/what-is-icosema#ref-1).

Its authors call the results hypothesis-generating. They say dedicated outcome trials are essential. Their appendix also carries a risk model labeled an illustration only. A figure from it is arithmetic about assumptions, unlike [a number needed to treat](https://buythisglp.com/research/glp1-number-needed-to-treat) built from counted events.

## How the regimens differ

IcoSema was given weekly in all three trials. In COMBINE 3, the comparator used daily basal insulin plus mealtime insulin [\[4\]](https://buythisglp.com/research/what-is-icosema#ref-4). Those findings apply to the regimens and adults studied and do not predict how a medication change would affect an individual patient.

## Frequently asked

What is IcoSema?

A weekly injection combining basal insulin icodec and semaglutide. It has EU marketing authorization as Kyinsu for type 2 diabetes.

Does IcoSema work better than insulin?

Against weekly insulin icodec alone, HbA1c fell 0.66 points more. Against basal-bolus therapy the difference was 0.06 points, which met the non-inferiority test, with 6.72 kg less weight and far fewer low-sugar episodes.

Why does the pooled analysis show 98% heterogeneity?

The I² of 98% reflects very different estimates across the two trials. Their insulin comparators differed, which may help explain the inconsistency. The pooled HbA1c difference was −0.37 percentage points, with a confidence interval that crossed zero.

Does IcoSema cause weight loss?

It depends on the comparison. Against basal-bolus insulin, weight favored IcoSema by 6.72 kg. Against semaglutide alone, weight rose 0.84 kg on IcoSema while it fell 3.70 kg on semaglutide.

Does it reduce cardiovascular risk?

The pooled analysis measured weight, blood pressure and lipids. It did not establish whether IcoSema reduces cardiovascular events.

## Sources

1.  \[1\] Alper A, et al. (2026). Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials Cardiovascular Diabetology - Endocrinology Reports. [PMID 42681675](https://pubmed.ncbi.nlm.nih.gov/42681675/)
2.  \[2\] Mathieu C, et al. (2025). Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial The Lancet Diabetes & Endocrinology. [PMID 40482671](https://pubmed.ncbi.nlm.nih.gov/40482671/)
3.  \[3\] Lingvay I, et al. (2025). Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial Diabetologia. [PMID 39820580](https://pubmed.ncbi.nlm.nih.gov/39820580/)
4.  \[4\] Billings LK, et al. (2025). Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial The Lancet Diabetes & Endocrinology. [PMID 40482670](https://pubmed.ncbi.nlm.nih.gov/40482670/)
5.  \[5\] European Medicines Agency (2026). Kyinsu: European Public Assessment Report European Medicines Agency. [Source](https://www.ema.europa.eu/en/medicines/human/EPAR/kyinsu)
6.  \[6\] European Medicines Agency (2026). Kyinsu: opinion on variation to marketing authorisation European Medicines Agency. [Source](https://www.ema.europa.eu/en/medicines/human/variation/kyinsu)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
